Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -1542.57% is 1366% below its 5-year average of -105.24%, near the low end of its 5-year range (-1542.57%–-27.87%).
513.99% below its 12-month average of -251.24%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -352.53%.
RETURN ON EQUITY (ROE)
-1542.57%
RETURN ON EQUITY (ROE) AVG TTM
-251.24%
RETURN ON EQUITY (ROE) AVG 3Y
-133.71%
RETURN ON EQUITY (ROE) AVG 5Y
-105.24%
RETURN ON EQUITY (ROE) AVG 10Y
-90.75%
RETURN ON EQUITY (ROE) AVG 15Y
-76.22%
RETURN ON EQUITY (ROE) AVG 20Y
-65.94%
CURRENT VS TTM AVG
-513.99%
CURRENT VS 3Y AVG
-1053.71%
CURRENT VS 5Y AVG
-1365.77%
CURRENT VS 10Y AVG
-1599.77%
CURRENT VS 15Y AVG
-1923.86%
CURRENT VS 20Y AVG
-2239.23%
SECTOR MEDIAN · HEALTHCARE
-40.76%
median of 687 covered companies
CURRENT VS SECTOR MEDIAN
-3684.52%
vs the sector median at left
Inovio Pharmaceuticals, Inc.
Market Cap
$79.46M
Return on Equity (ROE)
-1542.57%
TTM Avg
-251.24%
3Y Avg
-133.71%
5Y Avg
-105.24%
Market Cap
$79.04M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
Market Cap
$77.93M
Return on Equity (ROE)
-122.76%
TTM Avg
-82.75%
3Y Avg
-63.80%
5Y Avg
-49.10%
Market Cap
$78.06M
Return on Equity (ROE)
N/A
TTM Avg
354.96%
3Y Avg
354.96%
5Y Avg
354.96%
Market Cap
$80.78M
Return on Equity (ROE)
-130.67%
TTM Avg
-143.13%
3Y Avg
-106.90%
5Y Avg
-90.63%
Market Cap
$77.15M
Return on Equity (ROE)
-55.97%
TTM Avg
-55.58%
3Y Avg
-51.87%
5Y Avg
-151.31%
Market Cap
$77.39M
Return on Equity (ROE)
-94.81%
TTM Avg
-84.90%
3Y Avg
-70.34%
5Y Avg
-58.48%
Market Cap
$81.86M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$75.54M
Return on Equity (ROE)
-77.12%
TTM Avg
-270.75%
3Y Avg
-187.09%
5Y Avg
-136.77%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | $79.46M | -1542.57% | -251.24% | -133.71% | -105.24% |
| Citius Oncology, Inc. (CTOR)vs › | $79.04M | -114.06% | -50.52% | -45.18% | -45.18% |
| Pulmonx Corporation (LUNG)vs › | $77.93M | -122.76% | -82.75% | -63.80% | -49.10% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.06M | N/A | 354.96% | 354.96% | 354.96% |
| Nutriband Inc. (NTRB)vs › | $80.78M | -130.67% | -143.13% | -106.90% | -90.63% |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | -55.97% | -55.58% | -51.87% | -151.31% |
| Hyperfine, Inc. (HYPR)vs › | $77.39M | -94.81% | -84.90% | -70.34% | -58.48% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $81.86M | -85.65% | -57.41% | -45.73% | -8.61% |
| Outset Medical, Inc. (OM)vs › | $75.54M | -77.12% | -270.75% | -187.09% | -136.77% |
| SkinHealth Systems Inc. (SKIN)vs › | $76.14M | -51.09% | -35.88% | -53.46% | -40.30% |
ROE
-1542.6%
ROA
-136.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -352.53% |
| 2025-06-30 | -307.60% |
| 2025-03-31 | -188.25% |
| 2024-12-31 | -156.57% |
| 2024-09-30 | -153.49% |
| 2024-06-30 | -125.74% |
| 2024-03-31 | -132.29% |
| 2023-12-31 | -115.14% |
| 2023-09-30 | -119.12% |
| 2023-06-30 | -99.44% |
| 2023-03-31 | -121.17% |
| 2022-12-31 | -125.84% |
| 2022-09-30 | -124.60% |
| 2022-06-30 | -119.15% |
| 2022-03-31 | -92.47% |
| 2021-12-31 | -75.98% |
| 2021-09-30 | -48.74% |
| 2021-06-30 | -27.87% |
| 2021-03-31 | -32.37% |
| 2020-12-31 | -36.09% |
| 2020-09-30 | -55.49% |
| 2020-06-30 | -119.18% |
| 2020-03-31 | -66.56% |
| 2019-09-30 | -340.30% |
| 2019-06-30 | -217.44% |
| 2019-03-31 | -120.44% |
| 2018-12-31 | -111.54% |
| 2018-09-30 | -82.53% |
| 2018-06-30 | -84.95% |
| 2018-03-31 | -86.26% |
| 2017-12-31 | -61.95% |
| 2017-09-30 | -57.36% |
| 2017-06-30 | -64.45% |
| 2017-03-31 | -83.88% |
| 2016-12-31 | -59.81% |
| 2016-09-30 | -44.57% |
| 2016-06-30 | -24.14% |
| 2016-03-31 | -15.59% |
| 2015-12-31 | -16.61% |
| 2015-09-30 | -9.65% |
| 2015-06-30 | -17.40% |
| 2015-03-31 | -34.80% |
| 2014-12-31 | -32.48% |
| 2014-09-30 | -37.83% |
| 2014-06-30 | -55.70% |
| 2014-03-31 | -52.82% |
| 2013-12-31 | -125.88% |
| 2013-09-30 | -82.96% |
| 2013-06-30 | -92.40% |
| 2013-03-31 | -50.73% |
| 2012-12-31 | -57.25% |
| 2012-09-30 | -79.59% |
| 2012-06-30 | -62.53% |
| 2012-03-31 | -53.15% |
| 2011-12-31 | -32.24% |
| 2011-09-30 | -31.67% |
| 2011-06-30 | -23.52% |
| 2011-03-31 | -30.75% |
| 2010-12-31 | -37.88% |
| 2010-09-30 | -36.66% |
| 2010-06-30 | -39.36% |
| 2010-03-31 | -39.59% |
| 2009-12-31 | -40.31% |
| 2009-09-30 | -30.57% |
| 2009-06-30 | -53.88% |
| 2009-03-31 | -84.76% |
| 2008-12-31 | -67.86% |
| 2008-09-30 | -35.39% |
| 2008-06-30 | -41.20% |
| 2008-03-31 | -36.80% |
| 2007-12-31 | -36.10% |
| 2007-09-30 | -50.87% |
| 2007-06-30 | -42.58% |
| 2007-03-31 | -58.60% |
| 2006-12-31 | -68.75% |
| 2006-09-30 | -76.30% |
| 2006-06-30 | -62.08% |
| 2006-03-31 | -50.40% |
| 2005-12-31 | -65.17% |
| 2005-09-30 | -135.43% |
| 2005-06-30 | -110.18% |
| 2005-03-31 | -95.96% |
| 2004-12-31 | -70.57% |
| 2004-09-30 | -46.22% |
| 2004-06-30 | -31.50% |
| 2004-03-31 | -43.28% |
| 2003-12-31 | -31.00% |
| 2003-09-30 | -50.17% |
| 2003-06-30 | -145.96% |
